Gypto Pharma

What Gypto Pharma does

Gypto Pharma is an Egyptian Share Holding Company, structured as a state-owned entity under investment law 159, that operates the Egyptian Medicine City — a 180,000 m2 pharmaceutical manufacturing facility located in Al Obour Desert, Al Qalyoubia Governorate, inaugurated by President Abdel-Fattah El-Sisi in April 2021. The company manufactures pharmaceutical products across 13 therapeutic areas, including Neurology, Hepatology, Gastroenterology, Anti-infective, Pain killers, Ophthalmology, Dermatology, Metabolics & Anti Diabetic, Respirology, and Cardiology, with a portfolio of 250 registered products and an annual production capacity of 200 million units. Six flagship branded products (Schzocontrol, Solfenurin, Exosirylic, Zithotrac, Digicomag, and Quinospan) anchor the domestic product offering.

The company's manufacturing platform is anchored by two large plants: a sterile facility of 11,000 m2 with five streams (Eye Drops, Vials, Ampoules, Large Volume Parenteral, and Dental Anesthesia Cartridges) and a non-sterile facility of 9,500 m2 with four streams covering Solids, Liquids, Semi-Solids, and Soft Gelatin Capsules. Supporting infrastructure includes R&D laboratories that simulate production conditions for technology transfer, Quality Control laboratories, and ERP-based systems for batch monitoring and end-to-end traceability. The technology footprint is built around process reliability, regulatory compliance, and dose-form flexibility rather than proprietary AI or software-driven differentiation.

The business model rests on three revenue streams: domestic pharmaceutical product sales distributed through a medical representative sales force to healthcare providers, pharmacies, and hospitals; contract manufacturing for multinational pharmaceutical companies (including a flagship joint venture with Japan's Otsuka for IV solutions); and export of surplus production to African and Middle Eastern markets. Pricing is not publicly disclosed. Customers are segmented across Egyptian patients, multinational pharmaceutical partners, healthcare providers, and regional export markets, with the Otsuka Gypto JV serving as the strategic anchor for the contract manufacturing and export segments.

Name

Gypto Pharma

Legal name

Gypto Pharma

Website

https://gyptopharma.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Gypto Pharma is an Egyptian state-owned pharmaceutical manufacturer operating the Egyptian Medicine City, a 180,000 m2 facility producing 250 registered products across 13 therapeutic areas with 200 million units annual capacity, serving Egyptian patients, multinational pharma partners via contract manufacturing, and African and Middle Eastern export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical manufacturing
• Contract manufacturing
• Generic pharmaceuticals
• Sterile injectables
• Pharmaceutical exports

Headquarters

HQ city

Qalyub

HQ country

Egypt

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling pharmaceutical products covering 250 registered products across multiple therapeutic areas including Neurology, Hepatology, Gastroenterology, Anti-infective, Pain killers, Ophthalmology, Dermatology, Metabolics & Anti Diabetic, Respirology, and Cardiology. Products include Schzocontrol, Solfenurin, Exosirylic, Zithotrac, Digicomag, and Quinospan.
2. Contract Manufacturing: Joint production agreements with multinational pharmaceutical companies and international partners such as Otsuka. The company positions itself as a center of excellence for MNCs seeking manufacturing in the region.
3. Export: Targeting export as a key milestone with aim to cover Egyptian market needs and export excess production to African and regional markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Gypto Pharma manufactures a portfolio of 250 registered pharmaceutical products across 13 therapeutic areas, operating an 180,000 m2 manufacturing facility with 15 production lines and 200 million units of annual production capacity. The company also offers contract manufacturing services to multinational pharmaceutical companies through joint production agreements, exemplified by its joint-stock partnership with Japan's Otsuka. Manufacturing spans sterile dosage forms (Eye Drops, Vials, Ampoules, Large Volume Parenteral, Dental Anesthesia Cartridges) and non-sterile forms (Tablets, Capsules, Sachets, Effervescent Tablets, Syrups, Creams, Ointments, Soft Gelatin Capsules).

Product overview

Gypto Pharma is an Egyptian Share Holding Company operating as a pharmaceutical manufacturing hub. The company offers a diversified portfolio of 250 registered pharmaceutical products across 10 therapeutic areas including Neurology, Hepatology, Gastroenterology, Anti-infective, Pain killers, Ophthalmology, Dermatology, Metabolics & Anti-Diabetic, Respirology, and Cardiology. The product portfolio includes specific branded medications such as Quinospan 500 mg (Fluoroquinolone anti-infective), Digicomag Chewable Tablets (Antacid/Antiflatulent), Zithotrac 500 mg (Macrolide anti-infective), Exosirylic 500 mg (gallstone dissolution), Solfenurin 10 mg (urological), and Schzocontrol 400 mg (antipsychotic). Manufacturing capabilities include sterile facilities (Eye Drops, Vials, Ampoules, Large Volume Parenteral, Dental Anesthesia Cartridges) and non-sterile facilities (Tablets, Capsules, Sachets, Syrups, Creams, Ointments, and Soft Gelatin Capsules), with an annual production capacity of 200 million units.

Differentiator

Problem solved

Functional benefit

Products and services

• Schzocontrol 400 mg Film Coated Tablets Antipsychotic medication (Film Coated Tablets) for the treatment of acute and chronic schizophrenic disorder in which positive or negative symptoms are prominent. Targeted at healthcare providers, physicians, and pharmacists prescribing for neurology and psychiatry patients.
• Solfenurin 10 mg Film Coated Tablets Film coated tablets containing Solifenucin succinate 10 mg (equivalent to 7.5 mg Solifenucin) for urological treatment. Targeted at urology healthcare providers and patients requiring urological therapy.
• Exosirylic 500 mg Film Coated Tablets Bile acid preparation for dissolution of radiolucent (non-radio opaque) cholesterol gallstones not larger than 15 mm in diameter in patients with functioning gall bladder. Targeted at hepatology/gastroenterology healthcare providers.
• Zithotrac 500 mg Film Coated Tablets Macrolide anti-infective and antibacterial for systemic use for treatment of upper and lower respiratory tract infections and skin and soft tissue infections. Targeted at healthcare providers treating respiratory and dermatological infections.
• Digicomag Chewable Tablets Antacid and antiflatulent chewable tablets containing Calcium Carbonate, Magnesium Carbonate Heavy, and Simethicone for gastrointestinal relief. Targeted at gastroenterology patients and healthcare providers.
• Quinospan 500 mg Broad spectrum Fluoroquinolone anti-infective used for treatment of lower respiratory tract infections, exacerbation of chronic obstructive pulmonary disease, and bronchopulmonary infections caused by gram-negative bacteria. Targeted at respirology and infectious disease healthcare providers.
• Contract Manufacturing Services Joint production and contract manufacturing services offered to multinational pharmaceutical companies seeking manufacturing capacity in the MEA region. Services leverage the 180,000 m2 Egyptian Medicine City facility with 15 production lines and 200 million units annual capacity under cGMP and ISO 9001/2015 standards. Flagged via the Otsuka Gypto joint-stock entity targeting intravenous solutions for local and African markets.

Quantifiable outcome

• 200 million units annual production capacity across diverse dosage forms
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• OtsukaflagshipStrategic or Co-development Partner · 1 April 2021GYPTO Pharma signed a joint production agreement with Japanese health solutions company Otsuka to establish Otsuka Gypto as a joint-stock company. The partnership aims to cover Egyptian market needs and export excess production. Otsuka provides technical support while Gypto Pharma provides the 180,000 square metre facility and Egyptian labor. The partnership specifically targets intravenous solutions for local and African markets. This aligns with Egypt's strategy to become a regional hub for medical industrialization.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Gulf Pharmaceutical Industries (Julphar): UAE-based pharmaceutical manufacturer with broad branded generics and sterile injectables capabilities serving the Middle East and Africa. Comparable to Gypto as a regional pharma manufacturer targeting MEA export markets with similar dosage form coverage.

Broad incumbents

• Cipla: Indian-headquartered global pharmaceutical company with one of the largest branded generics and API portfolios in the world, including a meaningful presence in Africa through Cipla South Africa and other subsidiaries. Comparable to Gypto as a manufacturer supplying affordable generics across therapeutic categories to emerging markets.
• Aurobindo Pharma: Indian-headquartered global pharmaceutical manufacturer with a deep generics portfolio, sterile injectables, and APIs serving over 150 countries with strong emerging-markets exposure. Comparable to Gypto as a high-volume, cost-competitive generics and injectables manufacturer targeting similar export geographies.
• Aspen Pharmacare: Africa's largest pharmaceutical manufacturer with a broad portfolio across branded generics, sterile injectables, and APIs, plus a major presence in MEA. Comparable to Gypto as a pan-African pharma manufacturer competing for similar institutional, government, and export contracts.
• Viatris: Global healthcare company formed via the Mylan-Upjohn combination with one of the world's largest generics and biosimilars portfolios, including significant operations across the Middle East and Africa. Comparable to Gypto as a global branded generics manufacturer with deep emerging-markets distribution.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with a broad branded generics, injectables, and specialty portfolio across MENA and the US. Comparable to Gypto as a regional MENA pharma manufacturer with injectable manufacturing and African export ambitions.

Direct peers

• Otsuka Pharmaceutical: Japanese multinational pharmaceutical company and Gypto's joint venture partner in 'Otsuka Gypto.' Highly relevant as a partner/peer given the strategic JV for IV solutions in Egypt and Africa, and as a benchmark global pharma MNC using Gypto's facility.
• Eva Pharma: Egyptian pharmaceutical manufacturer with a broad branded generics portfolio across multiple therapeutic areas, serving Egyptian, African, and Middle Eastern markets. Directly comparable to Gypto as a domestic Egyptian pharma manufacturer competing for the same regional contract manufacturing and export opportunities.
• Pharco Pharmaceuticals: Leading Egyptian pharmaceutical company with a large branded generics portfolio, biosimilars capabilities, and significant regional and African export operations. Directly comparable to Gypto in therapeutic breadth, dosage form coverage, and MENA/Africa market focus.
• Egyptian International Pharmaceutical Industries Company (EIPICO): One of Egypt's largest pharmaceutical manufacturers with an extensive branded generics portfolio and significant export footprint to MEA and CIS markets. A direct competitor to Gypto across therapeutic categories, dosage forms, and export channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/gyptopharma
• Facebookfacebook.com/gyptophrama
• LinkedInlinkedin.com/company/gypto-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gypto Pharma